BOSTON– Care Access, the world’s leader in executing decentralized clinical trials at scale, has announced its upcoming involvement at four key industry conferences: CNS Summit, Outsourcing in Clinical Trials New England (OCTNE), Decentralized Trials & Research Alliance Annual Meeting (DTRA), and Decentralized Trials Digital Week. Care Access leaders will be onsite to discuss the common roadblocks to enrollment in clinical trials today; explore the potential of removing constraints imposed by traditional approaches to running clinical trials; and share examples of how the company’s innovative capabilities have helped sponsors to compress enrollment timelines and increase diversity in clinical trials. Care Access will also provide free COVID-19 rapid antigen testing for all attendees at the DTRA Annual Meeting and the CNS Summit.
“After a long 22 months, we’re thrilled to join these in-person industry-leading events to celebrate the advances the decentralized trial industry has made in the face of COVID-19,” said Ahmad Namvargolian, Care Access CEO. “Care Access strongly believes in delivering fast, predictable clinical trials by radically expanding and diversifying patient access, and these events provide us an opportunity to collaboratively discuss how to do that more effectively. It’s an honor to speak alongside some of the industry’s brightest and most talented leaders and organizations, and I look forward to building on our shared vision of imagining a more equitable and efficient clinical trial ecosystem.”
On the heels of a $220 million Series C Funding round, Care Access has continued to innovate and execute some of the industry’s most advanced clinical trials at scale. Through its participation in key events, the organization looks to continue this momentum and further its mission of bringing clinical research directly to patients, healthcare providers, and communities. Most notably, in its role as a founding member of DTRA, Care Access seeks to unite key stakeholders in groundbreaking decentralized research, as they share ideas, develop lasting connections, and collaborate on how to make patient-focused clinical trials accessible to everyone.
